Ezzati M, Lopez AD, Rodgers A, Hoorn SV, Murray CJL, Comparative Risk Assessment Collaborating Group: Selected major risk factors and global and regional burden of disease. Lancet. 2002, 360 (9343): 1347-1360. 10.1016/S0140-6736(02)11403-6.
Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003, 326 (7404): 1419-10.1136/bmj.326.7404.1419.
Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Comparative Risk Assessment Collaborating Group: Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet. 2003, 362 (9380): 271-280. 10.1016/S0140-6736(03)13968-2.
Cappuccio FP, Kerry SM, Micah FB, Rhule JP, Eastwood JB: A community programme to reduce salt intake and blood pressure in Ghana [ISRCTN88789643]. BMC Public Health. 2006, 6: 13-10.1186/1471-2458-6-13.
Chisholm D, Doran C, Shibuya K, Rehm J: Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev. 2006, 25 (6): 553-565. 10.1080/09595230600944487.
Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK: Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007, 334 (7599): 885-888. 10.1136/bmj.39147.604896.55.
Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M: The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007, 85 (4): 279-288. 10.2471/BLT.06.033647.
Harsha DW, Lin PH, Obarzanek E, Karanja NM, Caballero B: Dietary approaches to stop hypertension: a summary of study results. DASH Collaborative Research Group. J Am Diet Assoc. 1999, 99 (8 Suppl): S35-S39.
Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K: The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007, 370 (9603): 1929-1938. 10.1016/S0140-6736(07)61696-1.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ: Methods for the Economic Evaluation of Health Care Programmes. 2005, Oxford: Oxford University Press, 3
National Institute for Health and Clinical Excellence: Methods for development of NICE public health guidance. March 2006
World Health Organisation: Choosing Interventions that are Cost Effective (WHO-CHOICE). [Internet] Available from: http://www.who.int/choice/interventions/rf_tobacco/en/index.html. [Last accessed January 2011]
Moher D, Altman DG, Liberati A, Tetzlaff J: PRISMA statement. Epidemiology. 2011, 22 (1): 128-author reply 128
Nissinen A, Berrios X, Puska P: Community-based non-communicable disease interventions: lessons from developed countries for developing ones. Bull World Health Organ. 2001, 79 (10): 963-970.
Akkazieva B, Chisholm D, Akunov N, Jacab M: The health effects and costs of the interventions to control cardiovascular disease in Kyrgyzstan. 2009, [Internet] Available from: http://hpac.kg/images/pdf/prp60cvd_eng.pdf. [Last accessed Dec 2010]
Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002, 324 (7329): 71-86. 10.1136/bmj.324.7329.71.
Rubinstein A, García Martí S, Souto A, Daniel F, Augustovski F: Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost effectiveness and resource allocation: C/E. 2009, 7: 10-
Gaziano TA, Opie LH, Weinstein MC: Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006, 368 (9536): 679-686. 10.1016/S0140-6736(06)69252-0.
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990, 335 (8693): 827-838. 10.1016/0140-6736(90)90944-Z.
Robberstad B, Hemed Y, Norheim OF: Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country-the case of Tanzania. Cost effectiveness and resource allocation: C/E. 2007, 5: 3-
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361 (9374): 2005-2016.
Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000, 356 (9246): 1955-1964.
Murray CJL, Lauer JA, Hutubessy , Niessen L, Tomijima N, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003, 361 (9359): 717-725. 10.1016/S0140-6736(03)12655-4.
Ha DA, Chisholm D: Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2010, 26: 210-222.
Caro J, Klittich W, McGuire A, Ford I, Pettit J, Norrie J, Shepherd J: International economic analysis of primary prevention of cardiovascular disease with Pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. Eur Heart J. 1999, 20 (4): 263-268. 10.1053/euhj.1999.1193.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, Packard CJ: Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995, 333 (20): 1301-1307. 10.1056/NEJM199511163332001.
Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003, 326 (7404): 1423-10.1136/bmj.326.7404.1423.
Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003, 326 (7404): 1427-10.1136/bmj.326.7404.1427.
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985, 291 (6488): 97-104.
Gaziano TA, Steyn K, Cohen DJ, Weinstein M, Opie L: Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005, 112 (23): 3569-3576. 10.1161/CIRCULATIONAHA.105.535922.
Friend K, Levy DT: Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. Health Educ Res. 2002, 17 (1): 85-98. 10.1093/her/17.1.85.
Jamison DT: Disease control priorities in developing countries [electronic resource]. 2006, Washington: IBRD/The World Bank and Oxford University Press
Tobacco control in developing countries. Edited by: Jha P, Chaloupka FJ. 2000, Oxford, UK: Oxford Univ Pr, 237-272.
Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F: The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Tob Control. 2004, 13 (2): 190-195. 10.1136/tc.2003.004630.
Stead LF, Perera R, Bullen C, Mant D, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004, CD000146-3
Thavorn K, Chaiyakunapruk N: A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control. 2008, 17 (3): 177-182. 10.1136/tc.2007.022368.
Maguire TA, McElnay JC, Drummond A: A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001, 96 (2): 325-331. 10.1046/j.1360-0443.2001.96232516.x.
Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007, CD000031-1
Tosteson AN, Weinstein MC, Hunink MG, Mittleman MA, Goldman PA, Goldman L: Cost-effectiveness of population wide educational approaches to reduce serum cholesterol levels. Circulation. 1997, 95 (1): 24-30. 10.1161/01.CIR.95.1.24.
He FJ, MacGregor GA: Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004, CD004937-3
Law MR, Frost CD, Wald NJ: By how much does dietary salt reduction lower blood pressure? III–Analysis of data from trials of salt reduction. BMJ. 1991, 302 (6780): 819-824. 10.1136/bmj.302.6780.819.
Sellers DE, Crawford SL, Bullock K, McKinlay JB: Understanding the variability in the effectiveness of community heart health programs: a meta-analysis. Soc Sci Med. 1997, 44 (9): 1325-1339. 10.1016/S0277-9536(96)00263-8.
He FJ, MacGregor GA: How far should salt intake be reduced?. Hypertension. 2003, 42 (6): 1093-1099. 10.1161/01.HYP.0000102864.05174.E8.
Frost CD, Law MR, Wald NJ: By how much does dietary salt reduction lower blood pressure? II–Analysis of observational data within populations. BMJ. 1991, 302 (6780): 815-818. 10.1136/bmj.302.6780.815.
Huang G, Gu D, Wu X, Duan X, Xu X, Wu J, Xie B: Cost-effectiveness analysis of Beijing Fangshan cardiovascular prevention program in 1992–1997. Zhonghua Yu Fang Yi Xue Za Zhi. 2000, 34 (2): 78-80.
Redekop WK, Orlewska E, Maciejewski P, Rutten FFH, Niessen L: Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients. Pharmacoeconomics. 2008, 26 (10): 861-877. 10.2165/00019053-200826100-00006.
Scuffham PA, Kósa J: The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther. 2006, 20 (4): 309-317. 10.1007/s10557-006-8877-3.
Araujo D, Bahia L, Souza C: Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario. Int J Atheroscler. 2007, 2 (3): 189-194.
Gaziano TA, Galea G, Reddy KS: Scaling up interventions for chronic disease prevention: the evidence. Lancet. 2007, 370 (9603): 1939-1946. 10.1016/S0140-6736(07)61697-3.
Michos ED, Nasir K, Braunstein JB, Rumberger JA, Budoff MJ, Post WS, Blumenthal RS: Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006, 184 (1): 201-206. 10.1016/j.atherosclerosis.2005.04.004.
Karim R, Hodis HN, Detrano R, Liu CR, Mack WJ: Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008, 102 (7): 825-830. 10.1016/j.amjcard.2008.05.039.
Shah PK: Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?. J Am Coll Cardiol. 2010, 56 (2): 98-105. 10.1016/j.jacc.2009.09.081.
Schlendorf KH, Nasir K, Blumenthal RS: Limitations of the Framingham risk score are now much clearer. Prev Med. 2009, 48 (2): 115-116. 10.1016/j.ypmed.2008.12.002.
Bovet P, Gervasoni JP, Mkamba M, Balampama M, Lengeler C, Paccaud F: Low utilization of health care services following screening for hypertension in Dar es Salaam (Tanzania): a prospective population-based study. BMC Public Health. 2008, 8: 407-10.1186/1471-2458-8-407.